Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

2016845 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Leukemia

Volume 30, Issue 5, pp. 1044-1054

Field-Weighted Citation Impact: 70.53